Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Fear of discomfort and unnecessary treatment often deters patients from prostate cancer screening, despite the benefits of early detection. Prostate cancer can be asymptomatic, making early detection ...

The NHS will not be automatically inviting all men above a certain age to check for prostate cancer, unlike the approach for some other cancers. The UK National Screening Committee has suggested that ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...

ROSEVILLE, California — President Joe Biden's recent prostate cancer diagnosis is raising new questions about the disease and the value of screenings for men. Dr. David Yee, director of Urology and ...

Screening PSA levels at aged 65-69 may inform the decision to continue or discontinue prostate cancer screening after age 70 years, regardless of patient race and ethnicity. The absolute risks of ...